Pancreatic cancer remains a major unsolved health problem, with conventional cancer
treatments having little impact on disease course. Almost all patients who have pancreatic …

Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading
cause of cancer-related death in North America. Most patients present with locally advanced …

Background The prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) is
poor and selection of patients for surgery is challenging. This study examined the impact of a …

Pancreaticoduodenectomy (PD) with the possible addition of neoadjuvant or adjuvant
therapy is the standard of care in the United States for adenocarcinoma originating in the …

Objective The authors reviewed the pathology, complications, and outcomes in a
consecutive group of 650 patients undergoing pancreaticoduodenectomy in the 1990s …

This large-volume, single-institution review examines factors influencing long-term survival
after resection in patients with adenocarcinoma of the head, neck, uncinate process, body …

Objective The survival benefit of adjuvant radiotherapy and 5-fluorouracil versus observation
alone after surgery was investigated in patients with pancreatic head and periampullary …

Chronic pancreatitis is a well-known risk factor for pancreatic ductal adenocarcinoma (PDA)
development in humans, and inflammation promotes PDA initiation and progression in …

Background Mortality rates associated with pancreatic resection for cancer have steadily
decreased with time, but improvements in long-term survival are less clear. This prospective …

Invasive pancreatic ductal adenocarcinoma is an almost uniformly fatal disease. Several
distinct noninvasive precursor lesions can give rise to invasive adenocarcinoma of the …